ZENECA, the bioscience group that demerged from ICI last year made

what chairman Sir Denys Henderson called ''an encouraging start''.

Speaking at the annual meeting yesterday, he said the profit and cash

performance had been excellent despite difficult conditions.

Zeneca's three businesses -- pharmaceuticals, agrochemicals, and

specialties -- increased their combined sales by 12% to #4400m and their

trading profits before exceptional items by 21% to #713m. Exports did

particularly well, running at #4.6m a day. Zeneca Pharmaceuticals won

its first Queen's Award for Exports since demerger.

Sir Denys drew attention to the resilient performance of the

pharmaceutical division in spite of government healthcare reforms in

several of its major markets. Zeneca's pharmaceutical sales held up well

with newer products growing strongly. This has continued into the first

three months of the current year.

Reforms in the Common Agricultural Policy in Europe led to a 3%

decline in Zeneca's European agrochemical sales, this was offset by 14%

growth in worldwide sales. From a low base given the depth of the

recession, Specialties' sales rose by 10% and its profit by 92%. This

was largely due to various internal measures.

Capital investment for the future was continued with #313m spent in

1993, an increase of 17% on the previous year. Among the investments

were another Quorn plant at Billingham and plans were announced to build

a Gramoxone plant in China, where the group has identified growth

opportunities for its pharmaceuticals and specialties operations.

Spending on research and development grew by 14% to #519m.

In terms of current trading, the agrochemicals market was said to be

more stable than in the comparable period of 1993 and Specialty

Chemicals are trading satisfactorily against the background of improving

economic conditions. The pharmaecutical market is said to be even more

competitive than in 1993 but so far Zeneca's prices have seen little

erosion.

Sir Denys said: ''We have established a sound, international base of

excellent technology on which we can surely build in the years to

come.''

Zeneca's shares were encouraged by the confident tone of the AGM and

rose 8p to 705p. For the current year, the City is looking for profits

to grow by around 19% to #767m.